“So it's reasonable to assume that we will exceed that long-term guidance.”

In context

“ivan with Guggenheim Securities. Vamil Divan: So I have 2, if I could. So one just around -- thanks for the comment, 2025 and now 2026. My question is actually around the 2027 guidance you've given for Skyrizi and Rinvoq before you be clearly on track to exceed that. I'm curious your thoughts around updating the Street on sort of your longer-term outlook for Skyrizi and Rinvoq. And then the other question is on the aesthetic side. Can you just comment on the latest market share since you have for both BOTOX and Juvederm in the U.S? Robert Michael: So Vamil, this is Rob. I'll take your first question. So as you recall, we updated the 2027 guidance for Skyrizi and Rinvoq during the Q4 call earlier this year. And since then, we have raised the combined guidance for 2025 by over $1.7 billion. So it's reasonable to assume that we will exceed that long-term guidance. And I think that will be very clear when we provide 2026 guidance on the upcoming Q4 call. Now we have provided long-term guidance in the past really to help investors understand what the company will look like on the other side of the Humira LOE event. We said we would rapidly return to robust growth and deliver high single-digit compound revenue growth from '24 to '29. And we gave product specifics to support that high single-digit growth outlook. I mean sitting here today, we have clearly demonstrated the rapid return to growth. Our 2025 sales outlook exceeds our previous peak by almost $3 billion, and that's within 2 years of the LOE event. And the Street now reflects our high single-digit growth outlook for this decade. I'd say there appears to be good recognition of our momentum wit”